Dietary fat and risk of colon and rectal cancer with aberrant MLH1 expression, APC or KRAS genes by Weijenberg, M.P. et al.
  
 
Dietary fat and risk of colon and rectal cancer with
aberrant MLH1 expression, APC or KRAS genes
Citation for published version (APA):
Weijenberg, M. P., Luchtenborg, M., de Goeij, A. F., Brink, M., van Muijen, G. N. P., de Bruine, A. P., ...
van den Brandt, P. A. (2007). Dietary fat and risk of colon and rectal cancer with aberrant MLH1
expression, APC or KRAS genes. Cancer Causes & Control, 18(8), 865-879.
https://doi.org/10.1007/s10552-007-9032-6
Document status and date:
Published: 01/01/2007
DOI:
10.1007/s10552-007-9032-6
Document Version:
Publisher's PDF, also known as Version of record
Please check the document version of this publication:
• A submitted manuscript is the version of the article upon submission and before peer-review. There can
be important differences between the submitted version and the official published version of record.
People interested in the research are advised to contact the author for the final version of the publication,
or visit the DOI to the publisher's website.
• The final author version and the galley proof are versions of the publication after peer review.
• The final published version features the final layout of the paper including the volume, issue and page
numbers.
Link to publication
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these
rights.
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal.
If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license above,
please follow below link for the End User Agreement:
www.umlib.nl/taverne-license
Take down policy
If you believe that this document breaches copyright please contact us at:
repository@maastrichtuniversity.nl
providing details and we will investigate your claim.
Download date: 04 Dec. 2019
ORIGINAL PAPER
Dietary fat and risk of colon and rectal cancer with aberrant
MLH1 expression, APC or KRAS genes
Matty P. Weijenberg Æ Margreet Lu¨chtenborg Æ Anton F. P. M. de Goeij Æ
Mirian Brink Æ Goos N. P. van Muijen Æ Adriaan P. de Bruı¨ne Æ
R. Alexandra Goldbohm Æ Piet A. van den Brandt
Received: 7 June 2006 / Accepted: 20 June 2007 / Published online: 18 July 2007
 Springer Science + Business Media B.V. 2007
Abstract
Objective To investigate baseline fat intake and the risk
of colon and rectal tumors lacking MLH1 (mutL homolog 1,
colon cancer, nonpolyposis type 2) repair gene expression
and harboring mutations in the APC (adenomatous polyp-
osis coli) tumor suppressor gene and in the KRAS
(v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog)
oncogene.
Methods After 7.3 years of follow-up of the Netherlands
Cohort Study (n = 120,852), adjusted incidence rate ratios
(RR) and 95% confidence intervals (CI) were computed,
based on 401 colon and 130 rectal cancer patients.
Results Total, saturated and monounsaturated fat were
not associated with the risk of colon or rectal cancer, or
different molecular subgroups. There was also no associ-
ation between polyunsaturated fat and the risk of overall or
subgroups of rectal cancer. Linoleic acid, the most abun-
dant polyunsaturated fatty acid in the diet, was associated
with increased risk of colon tumors with only a KRAS
mutation and no additional truncating APC mutation or
lack of MLH1 expression (RR = 1.41, 95% CI 1.18–1.69
for one standard deviation (i.e., 7.5 g/day) increase in in-
take, p-trend over the quartiles of intake <0.001). Linoleic
acid intake was not associated with risk of colon tumors
without any of the gene defects, or with tumors harboring
aberrations in either MLH1 or APC.
Conclusion Linoleic acid intake is associated with colon
tumors with an aberrant KRAS gene, but an intact APC
gene and MLH1 expression, suggesting a unique etiology
of tumors with specific genetic aberrations.
Keywords Dietary Fats  Colorectal Neoplasms 
Epidemiology  Molecular
Introduction
Although dietary fat has been implicated in the etiology of
colorectal cancer [1], results from epidemiological studies
are inconsistent [2, 3] and often do not support an associ-
ation, as observed recently in the Women’s Health Study
[4]. Fortunately, current molecular techniques to detect
DNA alterations on a large scale allow studying molecular
endpoints for colorectal cancer, characterized by acquired
(epi) genetic defects in tumor DNA [5]. This approach may
improve our ability to observe associations between dietary
factors and cancer that may otherwise remain undetected.
A multistep model linking sporadic colorectal carcino-
genesis to molecular aberrations has been proposed [6–8],
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with DNA repair genes, tumor suppressor genes and
oncogenes, operating in multiple genetic pathways. About
10–20% of sporadic colon carcinomas are characterized by
microsatellite instability, predominantly due to promoter
methylation of the MLH1 (mutL homolog 1, colon cancer,
nonpolyposis type 2) DNA mismatch repair gene, which
prevents expression of the enzyme [9]. Up to 90% of colon
and rectum carcinomas are chromosomally instable [10,
11] and are associated with mutations in the APC (adeno-
matous polyposis coli) and TP53 (tumor protein 53) tumor
suppressor genes and in the KRAS (v-Ki-ras2 Kirsten rat
sarcoma viral oncogene homolog) oncogene [12]. How-
ever, simultaneous occurrence of mutations in these three
genes is rare suggesting that, even within this group of
chromosomally instable tumors, different genetic pathways
to colorectal cancer exist [13, 14]. Mutations in the APC
gene are found to occur relatively early in colorectal
tumorigenesis and are observed in up to 80% of both
adenomas and carcinomas [8, 15]. Mutations in the KRAS
gene are observed in approximately 10–20% of small
adenomas and 40–50% of larger adenomas and carcino-
mas, suggesting it to be an important event in the pro-
gression of adenoma to carcinoma [15]. Mutations in the
TP53 gene are postulated to affect relatively late stages of
colorectal carcinogenesis [15].
Breivik et al. proposed that the type of genetic insta-
bility in cancer cells reflects the selection pressures exerted
by specific carcinogens [16]. Bardelli et al. subsequently
tested this hypothesis in immortal genetically stable human
cells and concluded that exposure to specific carcinogens
can indeed select for tumor cells with distinct forms of
genetic instability and vice versa [17]. Therefore, DNA
adducts derived from dietary fat metabolism could also be
associated with colorectal tumors exhibiting chromosomal
instability. This is supported by the observations that
malondialdehyde (MDA), generated during lipid peroxi-
dation and arachidonic acid metabolism, can form DNA
adducts and induce G ﬁ T transversions and G ﬁ A
transitions in DNA [18, 19]. In addition, higher levels of
MDA-DNA adducts have been observed in colorectal tis-
sue of adenoma patients than in tissue of controls [20].
MDA levels are modulated by dietary factors, with poly-
unsaturated fatty acids, and specifically x-6 polyunsatu-
rated fatty acids, presumably increasing MDA levels [21].
This is in line with our previous report of a significant
association between the intake of linoleic acid, the most
abundant x-6 polyunsaturated fatty acid in the diet, and
increased risk of colon carcinomas with a mutated KRAS
gene within the Netherlands Cohort Study (NLCS) on diet
and cancer [22].
These observations and hypotheses prompted us to
investigate the associations between the intake of total fat
and different types of fat and the risk of colon and rectal
tumors lacking MLH1 expression and with and without
APC gene mutations, two early events in colorectal
tumorigenesis, independent of tumors harboring KRAS
gene mutations.
Materials and methods
Study population
The prospective NLCS was initiated in The Netherlands in
September 1986. The study design has been described in
detail elsewhere [23]. Briefly, at baseline a total of 58,279
men and 62,573 women, between the ages of 55 and
69 years, completed a self-administered food frequency and
lifestyle questionnaire. Incident cancer cases are identified
by monitoring of the entire cohort for cancer occurrence
through annual record linkage to the National Cancer Reg-
istry (NCR), consisting of nine regional cancer registries
throughout The Netherlands, and to PALGA, a nationwide
network and registry of histo- and cytopathology [24]. The
NCR and PALGA together provide a near 100% coverage of
the 204 municipalities included in the NLCS.
Accumulation of person-time in the cohort was esti-
mated through biennial vital status follow-up of a subco-
hort of 3,500 men and women who were randomly selected
after baseline exposure measurement [24]. Cases with
prevalent cancer other than non-melanoma skin cancer
were excluded from the subcohort, which left 3,346 men
and women for analysis next to all colorectal cancer cases
from the entire cohort. No subcohort members were lost to
follow-up. A flow diagram of subcohort members and pa-
tients on whom the analyses are based is given in Fig. 1.
The first 2.3 years of follow up were excluded because
of possible preclinical disease affecting exposure status and
because of incomplete nationwide coverage of PALGA
alone (i.e., not in combination with the NCR) in some of
the municipalities included in the NLCS. Within this per-
iod, 83 subcohort members deceased or were diagnosed
with cancer other than non-melanoma skin cancer, leaving
3,263 subcohort members for analysis. From 1989 to 1994,
929 incident cases with histologically confirmed colorectal
cancer were identified within the entire cohort, of whom
819 could also be linked to a PALGA report of the lesion.
The PALGA reports were used to identify and locate tumor
tissues from eligible colorectal cancer patients in 54
pathology laboratories throughout the Netherlands. Can-
cers were classified according to site as follows, colon:
cecum through sigmoid colon (ICD-O codes 153:0, 153.1,
153.2, 153.3, 153.4, 153.5, 153.6, 153.7), proximal colon
(ICD-O codes 153.0, 153.1, 153.4, 153.5, 153.6), distal
colon (ICD-O codes 153.2, 153,3, ‘53.7), rectosigmoid
(ICD-O code 154.0), and rectum (ICD-O code 154.1).
866 Cancer Causes Control (2007) 18:865–879
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Tissue samples
Approval for collection of archival tissue samples from
colorectal cancer patients was obtained from the Ethical
Review Board of University Maastricht, the NCR and
PALGA. The tissue specimen collection started in August
1999 and was completed in December of 2001. For five
percent of patients, tissue samples could not be retrieved
(44/819) due to administrative inconsistencies. Of 775
available tissue samples, 737 (95%) contained sufficient
tumor material for molecular analyses of MLH1 expression
and mutations in APC and KRAS genes.
Since the rectosigmoid can be considered as a clinically
applied term rather than an anatomically defined transi-
tional zone between the colon and rectum, the 85 patients
with a rectosigmoid tumor were excluded from data anal-
ysis. Moreover, the group of patients with a rectosigmoid
tumor was too small for adequate stratified analysis.
MLH1 expression analysis
Formalin-fixed, paraffin-embedded tissues were sectioned
at 4 lm and contained tumor tissue and normal adjacent
mucosa. Endogeneous peroxidase activity was blocked
with 3% H2O2. Slides were submitted to microwave anti-
gen retrieval in 1mM EDTA buffer (pH 8.0) and incubated
with 10% normal horse serum for 10 min at room tem-
perature. Then, sections were incubated overnight at 4C
with mouse monoclonal antibodies against MLH1 protein
(clone G168–15, PharMingen, San Diego, CA) at a 1:100
dilution. Antibody binding was detected by incubating the
sections at room temperature with the peroxidase-labeled
DAKO Envision System (DAKO, Carpinteris, CA) and
using DAB as a chromogen. Sections were counterstained
with haematoxylin.
Lesions were considered to lack MLH1 protein
expression when unequivocal absence of nuclear staining
of the tumor epithelial cells was observed. Nuclear
staining of normal epithelial and stromal cells or lym-
phocytes served as internal positive control. Two inves-
tigators reviewed the immunohistochemical staining
independently and discrepancies were re-examined and
discussed with a pathologist until consensus was reached.
MLH1 expression status was determined successfully in
98% of samples, i.e., 468 colon tumors and 173 rectum
tumors (Fig. 1).
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APC mutation analysis
The majority of somatic mutations in APC occur within the
mutation cluster region. Mutation analysis of the mutation
cluster region (codons 1,286–1,520), was performed on
archival adenocarcinoma specimens, using macrodissec-
tion followed by extraction of tumor DNA. Then nested
PCR was used to amplify the mutation cluster region in
four overlapping DNA fragments and the purified frag-
ments were sequenced. This procedure has been described
in detail elsewhere [25]. In brief, in a first round of PCR,
two overlapping fragments were generated, that served as
templates for a second round of PCR to amplify four
overlapping biotin-labeled PCR fragments that were sub-
sequently used for direct sequencing. The sequence profile
was analyzed on ALFexpress DNA Analysis System using
ALFwin software (Amersham Biosciences, Roosendaal,
The Netherlands). Evaluation of the sequence patterns and
data entry were independently performed by two observers.
Sensitivity and specificity was assessed by analyzing the
mutational status of APC in six colorectal cancer cell lines.
Both sensitivity and specificity were regarded to be satis-
factory since specific mutations in the mutation cluster
region of APC were confirmed in CaCo2 cells, SW480
cells and LOVO cells, as previously described [25, 26], and
wild type sequences were confirmed in HCT116, Colo205
and HT29, for the mutation cluster region of APC [25]. In
addition, the detection limit was 5% of mutated DNA [25].
Reproducibility of mutation analysis was regarded to be
satisfactory since 85% of duplicate analyses, from flank
PCR of genomic DNA to sequencing of the four fragments
(i.e., 61 out of 72 fragments), revealed identical mutation
status of APC [25].
From 47 colon cancer patients and 25 rectum cancer
patients, one or more fragments of the APC gene mutation
cluster region could not be amplified and these patients
were not included in this study, leaving 429 colon and 151
rectum cancer cases with successful analysis of the muta-
tion cluster region of the APC gene (Fig. 1).
KRAS mutation analysis
Mutation analysis of the exon1 fragment of the KRAS
oncogene, spanning codons 8–29, was performed on
archival adenocarcinoma specimens, using nested PCR,
followed by direct sequencing of purified fragments [27].
The detection limit was 5% mutated DNA. Reproduc-
ibility was regarded to be satisfactory, since 88% of
duplicate analyses, from tissue sectioning to DNA
sequencing (i.e., 28 out of 32), revealed identical muta-
tion status of KRAS [27]. Mutation analysis was per-
formed with success on 476 colon and 176 rectum cancer
cases (Fig. 1).
Exposure assessment
The 150–item semi-quantitative food frequency question-
naire concentrated on habitual consumption of food and
beverages during the year preceding the start of the study.
Mean individual nutrient intakes per day were computed
using the computerized Dutch food composition table of
1986 [28]. The questionnaire was validated against a 9-day
diet record [29]. Crude and energy-gender-adjusted (in
parentheses) correlation coefficients were 0.72 (0.52) for
total fat, 0.73 (0.58) for saturated fat and 0.73 (0.75) for
polyunsaturated fat [29]. For energy intake the correlation
coefficient was 0.74. On average, the questionnaire covered
91% of the energy intake assessed by the record intake.
Questionnaire data were key-entered twice and processed
for all incident cases in the cohort and for all subcohort
members in a manner blinded with respect to case/subco-
hort status.
For 7% of subjects (either cases or subcohort members),
dietary data were incomplete or inconsistent, and they were
excluded from the analyses. Questionnaires were consid-
ered incomplete when either: (1) more than 60 items were
left blank and less than 35 items were eaten at least once a
month; or (2) one or more item blocks (groups of items,
e.g., beverages) were left blank. Additional details are
given elsewhere [29]. This resulted in the availability of
3,048 subcohort members, 441 colon cancer cases for
whom MLH1 expression status was known, and 414 colon
and 136 rectal cancer cases for whom APC and KRAS
mutation status was known. No data-analyses were con-
ducted for lack of MLH1 expression in rectal cancer cases
since there were only two such cases in the cohort (Fig. 1).
Intake of specific fatty acids was based on a food
composition database with specific fatty acids derived from
the TRANSFAIR study [30]. For this database, the hundred
foods that contributed most to fat intake in the Dutch
dietary pattern were sampled and analyzed as methyl esters
of the fatty acids present in the foods. In the database, total
fat includes triglycerides and other lipids such as phos-
pholipids and sterols. The percentage of triglycerides in
total fat is assumed to be 93% on average, but varies across
food sources. Daily intakes of total fat (g/day), saturated fat
(g/day), monounsaturated fat (g/day), polyunsaturated fat
(g/day), and linoleic acid (C18:2, C9, 12) (g/day) and
linolenic acid (C18:3, C9, 12, 15) (g/day) as the main
constituents of polyunsaturated fat, were used as exposure
variables. Linoleic and linolenic acid were used as the most
abundant sources of x-6 polyunsaturated fatty acids and
x-3 polyunsaturated fatty acids in the diet. In all analyses,
the values for fat intake variables are adjusted for energy
intake by the residual method [31]. For data analyses,
quartiles of the intake of fat and different types of fats were
computed based on the distribution of subcohort members.
868 Cancer Causes Control (2007) 18:865–879
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Daily intake of dietary fiber (g/day), alcohol (g/day), fruit
(g/day), vegetables (g/day) and total energy (kJ/day) and
age at baseline (years), sex (men/women), body mass index
(kg/m2), non-occupational physical activity (<30 min/day,
30–60 min/day, 60–90 min/day, >90 min/day), family
history of colorectal cancer (yes/no) and smoking status
(never/ex/current) were regarded as potential confounders.
Statistical analysis
Data analyses were based on study participants for whom
data on fat intake and confounding variables were com-
plete, i.e., 2,948 subcohort members, 428 colon cancer
patients for whom MLH1 expression status was known,
and 401 colon cancer and 130 rectal cancer patients for
whom APC and KRAS mutation status was known
(Fig. 1).
Data analyses were conducted separately for overall
colon and rectal cancer, colon cancer lacking MLH1
expression, colon and rectal cancer with or without a
truncating APC mutation, described here as APC+ and
APC– tumors respectively. Truncating APC mutations lead
to the introduction of a stop codon and result in a truncated
and therefore, inactive APC protein. The analyses with
truncating APC mutations were also conducted separately
for the most common point mutations resulting in the
introduction of a stop codon, i.e., C:G ﬁ T:A or G:C ﬁ
T:A point mutations. As indicated previously, associations
between fat intake and KRAS mutated tumors have been
described in this population previously, and a positive
association between the intake of linoleic acid and KRAS
mutated colon tumors was observed [22]. Therefore, when
(borderline) significant associations were observed with
any of the colon tumor endpoints, analyses were repeated
excluding tumors harboring mutations in KRAS.
Since tumors may harbor multiple mutations it is diffi-
cult to assess whether observed associations are specific for
tumors with a particular gene defect. We therefore, con-
ducted additional analyses when (borderline) significant
associations were observed. In these analyses subgroups of
tumors were formed characterized by either the absence of
the three gene defects, or by defects in a single gene, i.e.,
either only lack of MLH1 expression, only a truncating
APC mutation or only an activating KRAS mutations.
Activating KRAS mutations are defined as mutations in
codons 12 and 13 of the KRAS gene leading to an altered
amino acid.
Mean values of the intake of fat variables (g/day), and
possible confounding variables including age at baseline
(years), dietary fiber (g/day), alcohol (g/day), intake of
fruit (g/day), vegetable (g/day), energy (kJ/day), and BMI
(kg/m2), as well as distributions of the variables sex,
family history of colorectal cancer (yes/no), smoking
status (never/ex/current smoker) and physical activity in
leisure time (<30, 30–60, 60–90, >90 min/day) were
evaluated for subcohort members, colon and rectal cancer
patients with or without a truncating APC mutation and
colon cancer patients lacking MLH1 expression. Differ-
ences in mean values of the continuous variables between
patients with or without truncating nonsense or frameshift
mutations in the mutation cluster region of the APC gene,
and between patients with or without MLH1 expression,
were tested using the Mann–Whitney-U-test since the
variables were not normally distributed among cases. The
distributions of the categorical variables between patients
with and without truncating APC mutations were tested
with the v2–test.
Incidence rate ratios (RR) and corresponding 95%
confidence intervals (CI) for colon and rectal cancer pa-
tients were estimated according to quartiles of intake of fat
variables, and one standard deviation increment of intake,
using Cox proportional hazards regression models. In
addition, associations were estimated for specific molecular
endpoints of the tumors.
Standard errors were estimated using the robust Huber–
White sandwich estimator to account for additional vari-
ance introduced by sampling the subcohort from the entire
cohort [32, 33]. The proportional hazards assumption was
tested using the scaled Schoenfeld residuals [34]. Tests for
dose response trends over the different quartiles and cate-
gories of fat intake were estimated by fitting the ordinal
exposure variables as continuous variables and evaluated
using the Wald test.
The covariates included in the multivariate analyses
were those found to significantly (p < 0.05) contribute to
the multivariate model for colon and/or rectal cancer (age
at baseline, sex, body mass index, family history of colo-
rectal cancer, and smoking status) or to influence the RR by
more than ten percent, as well as energy intake.
Results
Lack of expression in MLH1 was observed in 13% (54 out
of 428) of tumors from colon cancer patients (Table 1).
APC truncating mutations were observed in tumors from
32% of colon cancer patients (127 out of 401) and 44% of
rectal cancer patients (57 out of 130) (Table 1). C:G ﬁ
T:A transitions or G:C ﬁ T:A transversions that would
result in a stop codon were observed in 10% and 5% of
colon cancer patients and 12% and 5% of rectal cancer
patients, respectively. These figures are similar to the
percentages reported for the total group of colon and rectal
cancer patients for whom APC mutation status was avail-
able, but for whom dietary intake data were not always
complete [25].
Cancer Causes Control (2007) 18:865–879 869
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Colon and rectal cancer patients were generally older
and more frequently men than subcohort members
(Table 1). Colon cancer patients lacking MLH1 expression
in their tumor were significantly less often men than
patients with expression of the gene (41% vs. 56%). There
were no striking differences in fat intake between patients
and subcohort members or between patients with or with-
out MLH1 expression or APC mutations in their tumors.
Only rectal cancer patients with a tumor harboring a
truncating APC mutation had a higher intake of saturated
fat than rectal cancer patients without a truncating APC
mutation (p = 0.05).
Neither total fat nor different types of fat appeared to be
associated with overall colon cancer risk in this population
(Table 2). For different subgroups of colon cancer based on
absence of MLH1 expression or absence or presence of
APC truncating mutations in their tumors, total fat intake
and most of the specific types of fat intake variables were
also not associated with risk. However, polyunsaturated fat
intake, and especially linoleic acid intake, appeared to be
associated with an increased risk of colon tumors without
MLH1 expression and with colon tumors without APC
truncating mutations, but not with colon tumors with APC
truncating mutations (Table 2). For colon tumors without
MLH1 expression, the RR according to the quartiles of
linoleic acid intake were increased, though not signifi-
cantly, for all the categories of intake above the reference
(lowest quartile of intake), i.e., 1.66 (95% CI 0.69–3.98),
2.14 (95% CI 0.91–5.00) and 2.02 (95% CI 0.86–4.76) for
the second through the fourth quartiles respectively, and
the test for linear trend was borderline significant
(p = 0.08). A similar trend was observed for the risk of
colon tumors without APC truncating mutations (RR over
the quartiles of linoleic acid intake: 1.50 (95% CI
1.02–2.21), 1.68 (95% CI 1.15–2.45) and 1.44 (95% CI
0.99–2.11) respectively, p-trend = 0.05 (Table 2). Addi-
tional analyses for subgroups of colon tumors with specific
truncating point mutations in APC did not show any
associations with the intake of fat or different types of fat
(results not shown).
For overall rectal cancer, associations with the intake
of total fat or different types of fat were not observed
(Table 3). Also after taking account of truncating APC
mutations in rectal tumors, none of the fat intake vari-
ables were significantly associated with risk of rectal
cancer. Only the intake of saturated fat appeared to be
inversely associated with rectal tumors without APC
truncating mutations (RR for the highest versus the
lowest quartile of intake: 0.46 (95% CI 0.22–0.97),
p-trend = 0.07) (Table 3). For rectal tumors with specific
types of APC truncating mutations no associations were
observed with any of the fat intake variables (results not
shown).
Additional analyses were conducted to assess whether
the observed associations of polyunsaturated fat intake, and
especially linoleic acid intake, with the increased risk of
colon tumors lacking MLH1 expression and with the
increased risk of colon tumors without APC truncating
mutations, were observed because of an underlying asso-
ciation with colon tumors harboring a KRAS mutation, as
previously observed [22]. Excluding tumors with a KRAS
mutation resulted in the absence of a statistically significant
association of polyunsaturated fat intake and linoleic acid
intake with colon tumors lacking MLH1 expression
(p-trend = 0.34 and 0.12, respectively) and those lacking
APC tuncating mutations (p-trend = 0.77 and 0.99,
respectively). Intake of polyunsaturated fat or linoleic acid
was neither associated with the risk of colon cancer without
any of the three gene defects, nor with the risk of colon
cancer only lacking MLH1 expression, nor with the risk of
colon cancer with only truncating APC mutations
(Table 4). With increasing intake of polyunsaturated fat
and of linoleic acid, a strongly increased risk of colon
cancer with only activating KRAS mutations was observed
(Table 4) (p-trend £ 0.001 for both polyunsaturated fat and
linoleic acid intake). The RRs for one standard deviation
increase in intake were 1.40 (95% CI 1.17–1.68) and 1.41
(95% CI 1.18–1.69), respectively. The RRs for polyun-
saturated fat (not shown) and linoleic acid intake were of
similar size when estimated separately for men (1.41, 95%
CI 1.15–1.72 for 1 standard deviation increase in linoleic
acid intake) and women (1.42, 95% CI 0.96–2.10), and
were elevated for proximal (1.23, 95% CI 0.99–1.53) and
distal colon cancer (1.53, 95% CI 1.21–1.95). Likewise, a
positive association was observed for all colorectal cancers
(1.24, 95% CI 1.06–1.47 and p-trend = 0.01), based on a
total of 87 cases (i.e., including the rectosigmoid).
Likewise, additional analyses were conducted for satu-
rated fat intake in relation to risk of rectal cancer without
APC truncating mutations, also excluding individuals with
a KRAS mutation and lack of MLH1 expression. The
association did not change substantially. Again, only the
highest level of intake showed a significant reduced risk of
cancer compared to the reference category (RR 0.40 95%
CI 0.14–1.15, p-trend = 0.09).
Discussion
In this prospective study, we observed that the intake of
total, saturated and monounsaturated fat was not associated
with the risk of colon cancer, rectal cancer, or the different
molecular subgroups of cancer based on lack of MLH1
expression or truncating mutations in the APC gene. This
was also found for polyunsaturated fat intake and rectal
cancer. However, linoleic acid showed an association with
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increased risk of colon tumors with only an activated KRAS
mutation and no additional truncating APC mutation or
lack of MLH1 expression.
None of the other epidemiological studies report on
specific fatty acids and the risk of molecular surrogate end-
points for colon or rectal cancer or adenomas [35–43].
Some of these studies report on various types of fat
depending on saturation level, but the results are incon-
sistent across the studies [35, 38, 41, 42] including the
current study.
Diergaarde et al. observed unsaturated fat intake to be
associated with increased colon carcinomas with a trun-
cating APC mutation [38]. No distinction was made
between mono- and polyunsaturated fats. In our study, we
did not observe any association between various types of
fat intake and risk of colon or rectal cancer with or without
truncating APC mutations after patients also harboring a
KRAS mutation in their tumor were excluded from the
analyses. We observed a possible inverse association be-
tween saturated fat intake and risk of rectal tumors without
a truncating APC mutation. However, the association was
weak, did not increase gradually according to the quartiles
of intake and was only a result of the reduced risk in the
highest category of intake. Furthermore, in absence of a
biological explanation for this finding and considering the
large number of associations investigated, the observation
may best be attributed to chance.
Slattery et al. observed saturated and monounsaturated
fats, but not polyunsaturated fat, to be associated with in-
creased risk of colon tumors with specific KRAS mutations,
i.e., a G ﬁ T transversion at codon 12 [41]. No distinction
was made between x-6 and x-3 fatty acids. We observed
an association between polyunsaturated fat intake, espe-
cially linoleic acid, and increased risk of colon tumors with
a KRAS mutation, regardless of the type of mutations [22].
Finally, Bautista et al. observed an inverse association
between monounsaturated fats, mostly derived from olive
oil in the Spanish diet, and risk of colon cancer without
KRAS mutations [35]. Since olive oil was rarely consumed
by this elderly Dutch population in the years preceding
1986 (the cohort baseline), this could explain the lack of
association for this type of fat in our study. However, a
recent Dutch case–control study on risk factors for colo-
rectal adenomas showed a significant positive association
between monounsaturated fats and adenoma risk [42].
Several factors hamper comparisons between our find-
ings and those of other epidemiological studies and may in
part explain observed inconsistencies. First, our study is the
first large prospective cohort study incorporating molecular
end-points for colon and rectal cancer. One of the other
studies was a cross-sectional case–case comparison study
[40], and the others were case–control studies of varying
size (ranging from 108 to 1,510 cases) [35–39, 41–43].
Second, varying end-points were considered. Three of the
other studies focused on adenomas instead of carcinomas
[37, 40, 42], and three studies also incorporated rectal
tumors but did not distinguish between colon and rectum
[35, 37, 42].
Previously, we reported the association between linoleic
acid intake and increased risk of colon tumors with KRAS
mutations (adjusted RR for one standard deviation of
increase 1.22 (95% CI 1.05–1.42)) [22]. Now, we report
that the association appears to be confined to those colon
tumors with activating KRAS mutations and an otherwise
intact APC gene and with MLH1 expression. In addition,
the association appears to be robust since RRs clearly
increase over the quartiles of linoleic acid intake and the
RRs for one standard deviation increase in linoleic acid
intake are similar for men and women, and is increased for
proximal and distal colon cancer as well as for overall
colorectal cancer, including the rectosigmoid. The acti-
vating KRAS mutations at codons 12 and 13 are predomi-
nantly G ﬁ T and G ﬁ A mutations [27] which could be a
result of MDA DNA adduct formation [18, 19] associated
with increased x-6 polyunsaturated fat intake [21].
Therefore, even though chance cannot be ruled out and
verification by others is warranted, the association seems
quite plausible.
Still several issues remain puzzling. First, why is the
observed association for linoleic acid confined to colon
cancer and not rectum cancer with only a KRAS mutation?
The multistep model for molecular aberrations underlying
colorectal carcinogenesis is likely to apply equally for both
tumor subsites [7, 8, 15]. However, lack of MLH1
expression in our study is rare among rectum cancer
patients and there is growing evidence for differences in
the etiology of colon and rectal tumors [33].
Second, why is the association with linoleic acid
observed for KRAS and not for truncating APC gene
mutations? It is unlikely that adduct formation selectively
occurs in one gene but not in the other. However, KRAS is
an oncogene requiring only one mutation for the gene to be
activated, whereas APC is a tumor suppressor gene
requiring an additional aberration in the other allele for loss
of function. In addition, more than half of the patients with
an APC mutation had multiple mutations in this gene [25],
complicating data analyses and interpretation. Additional
analyses for subgroups of colon tumors with specific
truncating point mutations in APC did not show any
associations with the intake of fat or different types of fat.
This still does not satisfy our third query, i.e., why are
the associations specifically confined to this subgroup of
colon cancer patients whose tumors are characterized by
activating KRAS mutations, and not truncating APC
mutations or lack of MLH1 expression? It is speculative,
but plausible, that when KRAS is the only one of the three
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genes affected, the mutation may more likely be the result
of exogenous exposure, for example a relatively high
linoleic acid intake. In contrast, when a KRAS mutation
co-occurs with a mutation in APC or, although more rarely,
in addition to a defective MLH1, these other early gene
defects also had a role in tumor formation and may have
resulted in a mutator phenotype leading to mutations in
other genes (such as the KRAS gene) irrespective of
exogenous factors. Since there is no information on the
timing of genetic aberrations in this type of human studies,
we cannot verify this with our data. Aberrations in other
genes, not available for this study, but possibly involved in
early tumorigenesis of colorectal cancer, could not be ac-
counted for in analyses and may have influenced results.
However, a recent systematic sequence analysis of 13,023
exons in individual colorectal cancers showed that the
prevalence of mutations other than in APC, KRAS and
TP53 is rather low [44], and mutations in TP53 is not an
early event in colorectal carcinogenesis. Finally, results are
based on relatively small numbers of patients, especially in
the reference group of polyunsaturated fat or linoleic acid
intake (four patients, see Table 4), and point estimates of
RRs for quartiles of intake of polyunstaturated fat or
linoleic acid should therefore, be interpreted cautiously.
Nevertheless, as discussed previously, the association
appears to be robust when regarding the results for one
standard deviation increase in linoleic acid intake (based on
a total of 65 patients). Therefore, Breivik and Glauder-
nack’s hypothesis for distinct carcinogens to exert their
effect on two proposed types of genetic instability, i.e.,
microsatellite instability and chromosomal instability [16],
may be extended to the potential effect of carcinogens on
more specific genetic pathways to colorectal tumorigenesis,
as for example the KRAS mutated pathway.
The data from this large prospective cohort study sug-
gest that linoleic acid intake is strongly associated with
colon tumors with an aberrant KRAS gene, but an intact
APC gene and MLH1 expression. Verification in other
studies is warranted. Possibly, tumors revealing the
involvement of distinct genetic pathways on the basis of
specific genetic aberrations, may have a unique etiology.
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